394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
| Autor: | Tarantino, P., Kim, S.E., Chan, N.N.N., Hughes, M.E., Smith, K., D’Amico, O.R., Kusmick, R., Pereslete, A.M., Alder, L., Anders, C., Morganti, S., Garrido-Castro, A.C., Lorusso, P., Lustberg, M., Sammons, S., Lin, N., Li, T., Tayob, N., Rimm, D., Tolaney, S.M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S384-S385 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|